ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men.Journal of the International AIDS Society · 2019Pooled it
- Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Pooled it
- Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis.Infection · 2017Pooled it
- Longitudinal trajectories of sexual behavior and incident hepatitis C reinfection among men who have sex with men with HIV.PloS one · 2025Article
- Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).International journal of epidemiology · 2024Article
- Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.The Journal of infectious diseases · 2023Article
- Article
- Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.MMWR. Morbidity and mortality weekly report · 2022Article
- Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV.Viruses · 2022Observational
- Article
- High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.The International journal on drug policy · 2021Article
- The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.Journal of viral hepatitis · 2021Article
- Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach.Journal of market access & health policy · 2021Article
- Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention.Statistical communications in infectious diseases · 2021Article
- Article
- What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.BMC infectious diseases · 2020Article
- Modeling based response guided therapy in subjects with recent hepatitis C infection.Antiviral research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 3 countries.
Funding
Abstract
backgroundWe report on the hepatitis C virus (HCV) epidemic among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) in the United Kingdom and model its trajectory with or without scaled-up HCV direct-acting antivirals (DAAs).
methodsA dynamic HCV transmission model among HIV-diagnosed MSM in the United Kingdom was calibrated to HCV prevalence (antibody [Ab] or RNA positive), incidence, and treatment from 2004 to 2011 among HIV-diagnosed MSM in the UK Collaborative HIV Cohort (UK CHIC). The epidemic was projected with current or scaled-up HCV treatment, with or without a 20% behavioral risk reduction.
resultsHCV prevalence among HIV-positive MSM in UK CHIC increased from 7.3% in 2004 to 9.9% in 2011, whereas primary incidence was flat (1.02-1.38 per 100 person-years). Over the next decade, modeling suggests 94% of infections are attributable to high-risk individuals, comprising 7% of the population. Without treatment, HCV chronic prevalence could have been 38% higher in 2015 (11.9% vs 8.6%). With current treatment and sustained virological response rates (status quo), chronic prevalence is likely to increase to 11% by 2025, but stabilize with DAA introduction in 2015. With DAA scale-up to 80% within 1 year of diagnosis (regardless of disease stage), and 20% per year thereafter, chronic prevalence could decline by 71% (to 3.2%) compared to status quo in 2025. With additional behavioral interventions, chronic prevalence could decline further to <2.5% by 2025.
conclusionsEpidemiological data and modeling suggest a continuing HCV epidemic among HIV-diagnosed MSM in the United Kingdom driven by high-risk individuals, despite high treatment rates. Substantial reductions in HCV transmission could be achieved through scale-up of DAAs and moderately effective behavioral interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.